scispace - formally typeset
K

Kari Alitalo

Researcher at University of Helsinki

Publications -  844
Citations -  122462

Kari Alitalo is an academic researcher from University of Helsinki. The author has contributed to research in topics: Angiogenesis & Vascular endothelial growth factor C. The author has an hindex of 174, co-authored 817 publications receiving 114231 citations. Previous affiliations of Kari Alitalo include Mount Sinai Hospital, Toronto & Cornell University.

Papers
More filters
Journal ArticleDOI

VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development.

TL;DR: In this paper, the authors reported the cloning and characterization of mouse VEGF-C, which is produced as a disulfide-linked dimer of 415 amino acid residue polypeptides.
Journal ArticleDOI

Lymphangiogenesis and cancer metastasis.

TL;DR: In this paper, the authors reviewed recent experimental and clinico-pathological data indicating that growth factors that stimulate lymphangiogenesis in tumours are associated with an enhanced metastatic process.
Journal ArticleDOI

Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma.

TL;DR: It is shown that the homogeneously staining regions of the COLO 320 HSR marker chromosome contain amplified c- myc, and it seems reasonable to suspect that amplification of c-myc may have contributed to tumorigenesis.
Journal ArticleDOI

Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma.

TL;DR: No staining for LNA-1 is seen in samples from multiple myeloma, prostate cancer, and angiosarcoma, supporting the absence of any etiological link between these diseases and HHV-8.
Journal ArticleDOI

VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.

TL;DR: Mouse models of lymphoedema have established VEGF-C as a promising agent for pro-lymphangiogenic therapy and VEGFR-3 has also been shown to be important for angiogenesis, acting together with V EGF/VEGFR-2 and Dll4/Notch signalling to control angiogenic sprouting.